Peptide-Therapy
How Somatostatin-Analog Clinical Evidence Shoul...
Somatostatin-analog clinical evidence should be interpreted according to the specific analog, formulation, receptor profile, study population, pharmacokinetic exposure, endpoint, comparator, and duration studied. Evidence that octreotide, lanreotide, pasireotide, or another...
How Somatostatin-Analog Clinical Evidence Shoul...
Somatostatin-analog clinical evidence should be interpreted according to the specific analog, formulation, receptor profile, study population, pharmacokinetic exposure, endpoint, comparator, and duration studied. Evidence that octreotide, lanreotide, pasireotide, or another...
Why Formulation, Dose, and Dosing Interval Must...
Formulation, dose, and dosing interval must be considered together in somatostatin-analog research because systemic exposure depends on both how much analog is administered and how rapidly the formulation releases it...
Why Formulation, Dose, and Dosing Interval Must...
Formulation, dose, and dosing interval must be considered together in somatostatin-analog research because systemic exposure depends on both how much analog is administered and how rapidly the formulation releases it...
How Depot and Sustained-Release Formulations In...
Depot and sustained-release formulations influence somatostatin-analog exposure by controlling how rapidly peptide molecules leave the administration site or delivery matrix and become available for systemic absorption. Instead of delivering the...
How Depot and Sustained-Release Formulations In...
Depot and sustained-release formulations influence somatostatin-analog exposure by controlling how rapidly peptide molecules leave the administration site or delivery matrix and become available for systemic absorption. Instead of delivering the...
How Immediate-Release and Long-Acting Somatosta...
Immediate-release and long-acting somatostatin-analog formulations differ primarily in how quickly the active analog becomes available and how long new molecules continue entering systemic circulation. Immediate-release preparations generally produce relatively rapid...
How Immediate-Release and Long-Acting Somatosta...
Immediate-release and long-acting somatostatin-analog formulations differ primarily in how quickly the active analog becomes available and how long new molecules continue entering systemic circulation. Immediate-release preparations generally produce relatively rapid...
How Structural Modification Can Extend Somatost...
Structural modification can extend somatostatin-analog exposure by preserving the residues and three-dimensional features needed for receptor recognition while removing or protecting molecular features that make native somatostatin rapidly susceptible to...
How Structural Modification Can Extend Somatost...
Structural modification can extend somatostatin-analog exposure by preserving the residues and three-dimensional features needed for receptor recognition while removing or protecting molecular features that make native somatostatin rapidly susceptible to...
Why Native Somatostatin Has a Short Biological ...
Native somatostatin has a short biological half-life because it is a small peptide hormone that is rapidly exposed to enzymatic degradation and efficient metabolic clearance after entering circulation. Human pharmacokinetic...
Why Native Somatostatin Has a Short Biological ...
Native somatostatin has a short biological half-life because it is a small peptide hormone that is rapidly exposed to enzymatic degradation and efficient metabolic clearance after entering circulation. Human pharmacokinetic...